{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:09:53Z","timestamp":1789016993526,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jlb.2026.100475","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:22:00Z","timestamp":1783092120000},"page":"100475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["ESR1 and PIK3CA circulating tumor DNA (ctDNA) mutation status as predictive biomarkers beyond variant allele fraction (VAF) in metastatic breast cancer"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9101-9131","authenticated-orcid":false,"given":"Nicola","family":"Fusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlb.2026.100475_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103108","article-title":"Circulating tumor DNA in breast cancer: from technological foundation to clinical implementation","volume":"144","author":"Lin","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jlb.2026.100475_bib2","series-title":"ESMO living guideline: metastatic breast cancer v1.2","author":"Gennari","year":"2025"},{"key":"10.1016\/j.jlb.2026.100475_bib3","first-page":"1","article-title":"The use of cell-free DNA (cfDNA)\/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer","author":"Bello","year":"2026","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jlb.2026.100475_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2023.100002","article-title":"Liquid biopsy: cell-free DNA based analysis in breast cancer","author":"Venetis","year":"2023","journal-title":"J Liq Biopsy"},{"issue":"12","key":"10.1016\/j.jlb.2026.100475_bib5","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.trecan.2023.08.011","article-title":"Variant allele frequency: a decision-making tool in precision oncology?","volume":"9","author":"Boscolo Bielo","year":"2023","journal-title":"Trends Cancer"},{"issue":"5","key":"10.1016\/j.jlb.2026.100475_bib6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/CCO.0000000000000964","article-title":"Circulating tumor DNA in breast cancer: a biomarker for patient selection","volume":"35","author":"Agostinetto","year":"2023","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"10.1016\/j.jlb.2026.100475_bib7","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-19-0306","article-title":"Cell-free circulating tumor DNA variant allele frequency associates with survival in metastatic cancer","volume":"26","author":"Pairawan","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jlb.2026.100475_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jmoldx.2022.02.002","article-title":"Driver mutation variant allele frequency in circulating tumor DNA and association with clinical outcome in patients with non-small cell lung cancer and EGFR- and KRAS-mutated tumors","volume":"24","author":"Li","year":"2022","journal-title":"J Mol Diagn"},{"issue":"4","key":"10.1016\/j.jlb.2026.100475_bib9","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3390\/cancers16040782","article-title":"Variant allele frequency analysis of circulating tumor DNA as a promising tool in assessing the effectiveness of treatment in non-small cell lung carcinoma patients","volume":"16","author":"Galant","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jlb.2026.100475_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102642","article-title":"ESR1 mutations in HR+\/HER2-metastatic breast cancer: enhancing the accuracy of ctDNA testing","volume":"121","author":"Venetis","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jlb.2026.100475_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104786","article-title":"Integrating PIK3CA testing into clinical practice for advanced HR+\/HER2- breast cancer: an expert consensus","volume":"87","author":"De Angelis","year":"2026","journal-title":"Breast"},{"key":"10.1016\/j.jlb.2026.100475_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2026.100462","article-title":"Harmonizing definitions in liquid biopsy: a terminology framework by the international society of liquid biopsy","volume":"12","author":"Jantus-Lewintre","year":"2026","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.jlb.2026.100475_bib13","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.csbj.2019.10.004","article-title":"Applications and analysis of targeted genomic sequencing in cancer studies","volume":"17","author":"Bewicke-Copley","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.jlb.2026.100475_bib14","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.32074\/1591-951X-1216","article-title":"Part II - analytical phase","volume":"117","author":"Guerini-Rocco","year":"2025","journal-title":"Pathologica"},{"issue":"10","key":"10.1016\/j.jlb.2026.100475_bib15","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/gim.2017.26","article-title":"Using high-resolution variant frequencies to empower clinical genome interpretation","volume":"19","author":"Whiffin","year":"2017","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.jlb.2026.100475_bib16","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/1878-0261.13557","article-title":"Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors","volume":"18","author":"Kalashnikova","year":"2024","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2026.100475_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13039-025-00718-3","article-title":"What the VAF? A guide to the interpretation of variant allele fraction, percent mosaicism, and copy number in cancer","volume":"18","author":"Smith","year":"2025","journal-title":"Mol Cytogenet"},{"issue":"1","key":"10.1016\/j.jlb.2026.100475_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-40923-7","article-title":"Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice","volume":"16","author":"Florou-Chatzigiannidou","year":"2026","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jlb.2026.100475_bib19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.fmre.2025.12.002","article-title":"New opportunities and challenges for nonshedder tumors","volume":"6","author":"Li","year":"2026","journal-title":"Fundam Res"},{"issue":"6","key":"10.1016\/j.jlb.2026.100475_bib20","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/cells10061377","article-title":"Breast cancer with bone metastasis: molecular insights and clinical management","volume":"10","author":"Venetis","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.jlb.2026.100475_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/genes14061160","article-title":"Breast cancer with brain metastasis: molecular insights and clinical management","volume":"14","author":"Ivanova","year":"2023","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.jlb.2026.100475_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.jlb.2026.100475_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100301","article-title":"International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors","volume":"8","author":"Fusco","year":"2025","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.jlb.2026.100475_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104619","article-title":"Role of the International Society of Liquid Biopsy (ISLB) in establishing quality control frameworks for clinical integration","author":"Fusco","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.jlb.2026.100475_bib25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/bloodadvances.2018018895","article-title":"Systemic inflammation induces release of cell-free DNA from hematopoietic and parenchymal cells in mice and humans","volume":"3","author":"van der Meer","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jlb.2026.100475_bib26","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/1878-0261.12729","article-title":"The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA","volume":"14","author":"Henriksen","year":"2020","journal-title":"Mol Oncol"},{"issue":"4","key":"10.1016\/j.jlb.2026.100475_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.tim.2024.06.005","article-title":"Cell-free DNA: a promising biomarker in infectious diseases","volume":"33","author":"Hu","year":"2025","journal-title":"Trends Microbiol"},{"issue":"4","key":"10.1016\/j.jlb.2026.100475_bib28","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00428-025-04156-9","article-title":"Laboratory practices for next-generation sequencing-based circulating tumor DNA analysis: insights from a comprehensive survey in China","volume":"488","author":"Peng","year":"2026","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.jlb.2026.100475_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106069","article-title":"Prediction model for ctDNA detectability in liquid comprehensive genomic profiling of advanced pancreatic cancer based on Japanese real-world data","volume":"11","author":"Ikushima","year":"2026","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.jlb.2026.100475_bib30","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-24-3200","article-title":"Timing of ctDNA analysis aimed at guiding adjuvant treatment in colorectal cancer","volume":"31","author":"Henriksen","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jlb.2026.100475_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.annonc.2025.11.002","article-title":"Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer","volume":"37","author":"Cabel","year":"2026","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jlb.2026.100475_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00609","article-title":"Clinicogenomic landscape and function of PIK3CA, AKT1, and PTEN mutations in breast cancer","volume":"10","author":"Tao","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100475_bib33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3389\/fonc.2021.644737","article-title":"PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"11","author":"Fusco","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.jlb.2026.100475_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054522","article-title":"Drugging the PI3K\/AKT\/mTOR pathway in ER+ breast cancer","volume":"24","author":"Alves","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jlb.2026.100475_bib35","doi-asserted-by":"crossref","first-page":"546","DOI":"10.32074\/1591-951X-1531","article-title":"Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+\/HER2- metastatic breast cancer","volume":"117","author":"Malapelle","year":"2025","journal-title":"Pathologica"},{"issue":"12","key":"10.1016\/j.jlb.2026.100475_bib36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14737159.2025.2576021","article-title":"ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer","volume":"25","author":"Yarunin","year":"2025","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jlb.2026.100475_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100314","article-title":"Harmonization trial on ESR1 testing strategies in ER+\/HER2- breast cancer patients: an Italian experience","volume":"9","author":"Pepe","year":"2025","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.jlb.2026.100475_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100331","article-title":"ESR1 analysis of liquid biopsy in breast cancer, one-year routine experience of an Italian clinical referral center","volume":"10","author":"Maloberti","year":"2025","journal-title":"J Liq Biopsy"},{"issue":"28","key":"10.1016\/j.jlb.2026.100475_bib39","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-Positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jlb.2026.100475_bib40","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-Mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.jlb.2026.100475_bib41","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1021\/acs.analchem.2c00446","article-title":"Real-time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: feasibility and cross-validation with NGS","volume":"94","author":"Callens","year":"2022","journal-title":"Anal Chem"},{"issue":"11","key":"10.1016\/j.jlb.2026.100475_bib42","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising <em>ESR1<\/em> mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2026.100475_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10549-025-07839-8","article-title":"The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6","volume":"215","author":"Oliveira","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.jlb.2026.100475_bib44","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/s41571-025-01066-2","article-title":"SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine","volume":"22","author":"Medford","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.jlb.2026.100475_bib45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/fon-2022-1196","article-title":"Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment","volume":"19","author":"Turner","year":"2023","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.jlb.2026.100475_bib46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"22","author":"Rugo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jlb.2026.100475_bib47","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with Inavolisib in PIK3CA-Mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jlb.2026.100475_bib48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12282-024-01640-z","article-title":"Capivasertib and fulvestrant for patients with HR-positive\/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial","volume":"32","author":"Tokunaga","year":"2025","journal-title":"Breast Cancer"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:30:20Z","timestamp":1789014620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426000214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":48,"alternative-id":["S2950195426000214"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100475","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESR1 and PIK3CA circulating tumor DNA (ctDNA) mutation status as predictive biomarkers beyond variant allele fraction (VAF) in metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100475"}}